Lisle M. Nabell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Lisle M. Nabell has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Alicia K. Morgans
Dana-Farber Cancer Institute, Boston, MA, USA
39 shared publications - Bernhard J. Eigl
Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada
39 shared publications - Daniel Peter Petrylak
Smilow Cancer Center, Yale School of Medicine, New Haven, CT
39 shared publications - David D. Chism
Thompson Cancer Survival Center, Knoxville, USA
39 shared publications - Elisabeth I. Heath
Mayo Clinic Rochester Minnesota USA
39 shared publications - Evan Y. Yu
Fred Hutchinson Cancer Center 4 Clinical Research Division Seattle, Washington
39 shared publications
Latest Publications
- Top Cited Papers
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (1) , 32-45
Cardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors
PURPOSE: Cardiac dysfunction is the leading cause of mortality among 10-year breast cancer survivors. Limited information regarding long-term risks of cardiac dysfunction after cardiotoxic therapy (anthracyclines, trastuzumab/pertuzumab, radiation) has precluded development of surveillance guidelines for the survivors. METHODS: Patients with breast cancer who completed cardiotoxic therapy underwent echocardiographic screening every 2 years. New-onset cardiac dysfunction was defined as left ventricular ejection fraction (LVEF) P = .009) over 20 years from breast cancer diagnosis. CONCLUSION: These findings provide evidence to support echocardiographic surveillance for several years after cardiotoxic therapy and also suggest a need to examine the efficacy of management of cardiovascular risk factors to mitigate risk.
- 1 January 2025
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 43 (1) , 32-45
Top Cited PapersCardiac Dysfunction Among Breast Cancer Survivors: Role of Cardiotoxic Therapy and Cardiovascular Risk Factors
PURPOSE: Cardiac dysfunction is the leading cause of mortality among 10-year breast cancer survivors. Limited information regarding long-term risks of cardiac dysfunction after cardiotoxic therapy (anthracyclines, trastuzumab/pertuzumab, radiation) has precluded development of surveillance guidelines for the survivors. METHODS: Patients with breast cancer who completed cardiotoxic therapy underwent echocardiographic screening every 2 years. New-onset cardiac dysfunction was defined as left ventricular ejection fraction (LVEF) P = .009) over 20 years from breast cancer diagnosis. CONCLUSION: These findings provide evidence to support echocardiographic surveillance for several years after cardiotoxic therapy and also suggest a need to examine the efficacy of management of cardiovascular risk factors to mitigate risk.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400477
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Two cohorts of patients with cyclin-dependent kinase inhibitor 2A ( CDKN2A )–mutated tumors treated with palbociclib are reported: one with head and neck cancer (HNC) with both squamous and nonsquamous cell histologies, and one with histology-pooled (HP) cancers. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. For the HNC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. For the HP cohort, the null hypothesis of a DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points included OR, safety, progression-free survival, overall survival, duration of response, and duration of SD RESULTS: Seventy patients with HNC (N = 28) or HP cancers (N = 42) were treated with palbociclib. For the HNC cohort, DC and OR rates were 40% (one-sided 90% CI, 27 to 100) and 4% (95% CI, P = .002). For the HP cohort, DC and OR rates were 13% (one-sided 90% CI, 6 to 100) and 5% (95% CI, CDKN2A alterations, but not in the HP cohort.
- 1 October 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2400477
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
PURPOSE: Targeted Agent and Profiling Utilization Registry is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and targetable genomic alterations. Two cohorts of patients with cyclin-dependent kinase inhibitor 2A ( CDKN2A )–mutated tumors treated with palbociclib are reported: one with head and neck cancer (HNC) with both squamous and nonsquamous cell histologies, and one with histology-pooled (HP) cancers. METHODS: Eligible patients had measurable disease, Eastern Cooperative Oncology Group performance status 0-2, adequate organ function, and no standard treatment options. The primary end point was disease control (DC), defined as objective response (OR) or stable disease (SD) of at least 16+ weeks duration. For the HNC cohort, Simon's two-stage design with a null DC rate of 15% versus 35% (power = 0.85; α = .10) was used. For the HP cohort, the null hypothesis of a DC rate of 15% was rejected if the lower limit of a one-sided 90% CI was >15%. Secondary end points included OR, safety, progression-free survival, overall survival, duration of response, and duration of SD RESULTS: Seventy patients with HNC (N = 28) or HP cancers (N = 42) were treated with palbociclib. For the HNC cohort, DC and OR rates were 40% (one-sided 90% CI, 27 to 100) and 4% (95% CI, P = .002). For the HP cohort, DC and OR rates were 13% (one-sided 90% CI, 6 to 100) and 5% (95% CI, CDKN2A alterations, but not in the HP cohort.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S3: Additional characterization of consecutive OPSCC presentations in a single patient.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S2: Locating missed OPSCC fragment using intraoperative robot fluorescence.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Video S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Video S1: Late-resection intraoperative brightfield and robot fluorescence views of representative OPSCC cases.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Table S3: Representativeness of Study Participants.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S2: Additional characterization of bipolar forceps instrument and normal tissue fluorescence signals without the tumor in view.
- Open Access
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.
- 13 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Interim Phase II Results Using Panitumumab-IRDye800CW during Transoral Robotic Surgery in Patients with Oropharyngeal Cancer
Supplementary Figure S1: OPSCC EGFR H-scores.